Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Osimertinib and Tegavivint in First-Line Metastatic EGFR-Mutant NSCLC
NCT04780568Phase 1Recruiting
- Sponsor
- The Ohio State University Comprehensive Cancer Center – James Cancer Hospital
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegavivint in non-small cell lung cancer (NSCLC), sponsored by The Ohio State University Comprehensive Cancer Center – James Cancer Hospital. Primary endpoint: Maximum Tolerated Dose at 28 days. Started Jan 2022; status: recruiting.
02
Drugs
tegavivint
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04780568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04780568.